OmniAb, Inc.
Todd Pettingill, CFA has a strong background in business development, strategy, and mergers and acquisitions. Todd currently holds the position of Vice President of Business Development and Strategy at OmniAb, Inc. where they have been since July 2013. Prior to that, Todd worked as an Associate in Mergers and Acquisitions at Deutsche Bank from July 2012 to July 2013. Todd also has experience as a Senior Associate in Life Sciences at PwC from January 2007 to September 2010.
Todd Pettingill, CFA holds a Bachelor of Science (B.S) degree in Accounting from Brigham Young University, which they completed from 2003 to 2006. Subsequently, they pursued an M.B.A degree in Finance from the UCLA Anderson School of Management, where they studied from 2010 to 2012. In addition to their formal education, Todd has also obtained the Chartered Financial Analyst (CFA) certification. Furthermore, they hold an inactive Certified Public Accountant (CPA) certification.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.